Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2020 | Are biomarkers for Alzheimer’s disease ready for clinical practice?

Giancarlo Logroscino • 22 Oct 2020
CONy 2020
Alzheimer’s Disease Dementia

Giancarlo Logroscino, MD, PhD, Università degli Studi di Bari, Bari, Italy, discusses the use of biomarkers for Alzheimer’s disease (AD) in the clinic. Biomarkers can be used to diagnose AD by evaluating the expression of disease pathology. However, currently biomarkers are not at a point in which they can be translated to clinical or preclinical practice. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.

Disclosures

Giancarlo Logroscino is associate editor of the Journal Neuroepidemiology, Karger and PI or co-PI of several grants, mainly from national agencies.

More from Giancarlo Logroscino

6:13
COVID-19: managing neurodegenerative diseases in southern Italy
Giancarlo Logroscino • 22 Oct 2020
4:40
The reconstructed cohort design: tracking rare neurodegenerative diseases
Giancarlo Logroscino • 22 Oct 2020
3:08
The potential of biomarkers in dementia
Giancarlo Logroscino • 22 Oct 2020

Related Videos

10:24
Comparing cognitive profiles in multiple sclerosis vs. Alzheimer's disease
Laura Hancock et al. • 22 Mar 2024
4:49
Diagnostic utility of CSF biomarkers in patients with rapidly progressive dementia
Michael Geschwind • 23 Mar 2024
5:43
Introduction to rapidly progressive dementia: definitions and etiologies
Michael Geschwind • 23 Mar 2024
2:43
The key components of RPD assessment
Michael Geschwind • 23 Mar 2024
The content of VJNeurology is intended for healthcare professionals